Top

Published in:

Open Access 01-06-2018 | Review

From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders

Authors: Zuzanna Małgorzata Łukasik, Marcin Makowski, Joanna Samanta Makowska

Published in: Rheumatology International | Issue 6/2018

Abstract

Thrombosis and cardiovascular complications are common manifestations of a variety of pathological conditions, including infections and chronic inflammatory diseases. Hence, there is great interest in determining the hitherto unforeseen immune role of the main blood coagulation executor—the platelet. Platelets store and release a plethora of immunoactive molecules, generate microparticles, and interact with cells classically belonging to the immune system. The observed effects of platelet involvement in immune processes, especially in autoimmune diseases, are conflicting—from inciting inflammation to mediating its resolution. An in-depth understanding of the role of platelets in inflammation and immunity could open new therapeutic pathways for patients with autoimmune disorders. This review aims to summarize the current knowledge on the role of platelets in the patomechanisms of autoimmune disorders and suggests directions for future research.

de Gaetano G (2001) Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica 86:349–356PubMed

Patel SR, Hartwig JH, Italiano JE (2005) The biogenesis of platelets from megakaryocyte proplatelets. Journal of Clinical Investigation 115:3348–3354. https://doi.org/10.1172/JCI26891 PubMedPubMedCentralCrossRef

Machlus KR, Thon JN, Italiano JE (2014) Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation. Br J Haematol 165(2):227–236. https://doi.org/10.1111/bjh.12758 PubMedCrossRef

Garraud O, Cognasse F (2015) Are platelets cells? And if yes, are they immune cells? Front Immunol 6:70. https://doi.org/10.3389/fimmu.2015.00070 PubMedPubMedCentralCrossRef

Amaya-Amaya J, Montoya-Sánchez L, Rojas-Villarraga A (2014) Cardiovascular involvement in autoimmune diseases. Biomed Res Int 2014:367359. https://doi.org/10.1155/2014/367359 PubMedPubMedCentralCrossRef

Golebiewska EM, Poole AW (2015) Platelet secretion: from haemostasis to wound healing and beyond. Blood Rev 29:153–162. https://doi.org/10.1016/j.blre.2014.10.003 PubMedPubMedCentralCrossRef

Vieira-de-Abreu A, Campbell RA, Weyrich AS, Zimmerman GA (2012) Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol 34:5–30. https://doi.org/10.1007/s00281-011-0286-4 PubMedCrossRef

Cunningham M, Marks N, Barnado A, Wirth JR, Gilkeson G, Markiewicz M (2014) Are microparticles the missing link between thrombosis and autoimmune diseases? Involvement in selected rheumatologic diseases. Semin Thromb Hemost 40:675–681. https://doi.org/10.1055/s-0034-1387924 PubMedPubMedCentralCrossRef

Barry OP, Pratico D, Lawson JA, FitzGerald GA (1997) Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 99:2118–2127. https://doi.org/10.1172/JCI119385 PubMedPubMedCentralCrossRef

10.

Stokes KY, Granger DN (2012) Platelets: a critical link between inflammation and microvascular dysfunction. J Physiol 590:1023–1034. https://doi.org/10.1113/jphysiol.2011.225417 PubMedCrossRef

11.

Herter JM, Rossaint J, Zarbock A (2014) Platelets in inflammation and immunity. J Thromb Haemost 12:1764–1775. https://doi.org/10.1111/jth.12730 PubMedCrossRef

12.

Lam FW, Vijayan KV, Rumbaut RE (2015) Platelets and their interactions with other immune cells. Compr Physiol 5:1265–1280. https://doi.org/10.1002/cphy.c140074 PubMedPubMedCentralCrossRef

13.

Ghoshal K, Bhattacharyya M (2014) Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. Sci World J 2014:7818–7857. https://doi.org/10.1155/2014/781857 CrossRef

14.

Garraud O, Cognasse F (2010) Platelet Toll-like receptor expression: the link between “danger” ligands and inflammation. Inflamm Allergy Drug Targets 9:322–333. https://doi.org/10.2174/187152810793937991 PubMedCrossRef

15.

Li C, Li J, Li Y, Lang S, Yougbare I, Zhu G et al. (2012) Crosstalk between platelets and the immune system: old systems with new discoveries. Adv Hematol 2012:384685. https://doi.org/10.1155/2012/384685 PubMedPubMedCentralCrossRef

16.

Solpov A, Shenkman B, Vitkovsky Y, Brill G, Koltakov A, Farzam N et al (2006) Platelets enhance CD4+ lymphocyte adhesion to extracellular matrix under flow conditions: role of platelet aggregation, integrins, and non-integrin receptors. Thromb Haemost 95:815–821PubMedCrossRef

17.

Arman M, Krauel K (2015) Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis. J Thromb Haemost 13:893–908. https://doi.org/10.1111/jth.12905 PubMedCrossRef

18.

Cognasse F, Nguyen KA, Damien P, McNicol A, Pozzetto B, Hamzeh-Cognasse H et al (2015) The inflammatory role of platelets via their TLRs and Siglec receptors. Front Immunol 6:83. https://doi.org/10.3389/fimmu.2015.00083 PubMedPubMedCentralCrossRef

19.

Bennett JS, Berger BW, Billings PC (2009) The structure and function of platelet integrins. J Thromb Haemost 7:200–205. https://doi.org/10.1111/j.1538-7836.2009.03378.x PubMedCrossRef

20.

Peerschke EI, Yin W, Ghebrehiwet B (2010) Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 47:2170–2175. https://doi.org/10.1016/j.molimm.2010.05.009 PubMedPubMedCentralCrossRef

21.

Nurden AT (2011) Platelets, inflammation and tissue regeneration. Thromb Haemost 105:13–33. https://doi.org/10.1160/THS10-11-0720 CrossRef

22.

Morrell CN, Aggrey AA, Chapman LM, Modjeski KL (2014) Emerging roles for platelets as immune and inflammatory cells. Blood 123:2759–2767. https://doi.org/10.1182/blood-2013-11-462432 PubMedPubMedCentralCrossRef

23.

Rendu F, Brohard-Bohn B (2001) The platelet release reaction: granules’ constituents, secretion and functions. Platelets 12:261–273. https://doi.org/10.1080/09537100120068170 PubMedCrossRef

24.

Coppinger JA, Maguire PB (2007) Insights into the platelet releasate. Curr Pharm Des 13:2640–2646. https://doi.org/10.2174/138161207781662885 PubMedCrossRef

25.

Blair P, Flaumenhaft R (2009) Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 23:177–189. https://doi.org/10.1016/j.blre.2009.04.001 PubMedPubMedCentralCrossRef

26.

Stocker TJ, Ishikawa-Ankerhold H, Massberg S, Schulz C (2017) Small but mighty: platelets as central effectors of host defense. Thromb Haemost 117:651–661. https://doi.org/10.1160/TH16-12-0921 PubMedCrossRef

27.

Joshi S, Whiteheart SW (2017) The nuts and bolts of the platelet release reaction. Platelets 28:129–137. https://doi.org/10.1080/09537104.2016.1240768 PubMedCrossRef

28.

Manne BK, Xiang SC, Rondina MT (2017) Platelet secretion in inflammatory and infectious diseases. Platelets 28:155–164. https://doi.org/10.1080/09537104.2016.1240766 PubMedCrossRef

29.

Mancuso ME, Santagostino E (2017) Platelets: much more than bricks in a breached wall. Br J Haematol 178:209–219. https://doi.org/10.1111/bjh.14653 PubMedCrossRef

30.

Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP et al (2004) Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 103:2096–2104. https://doi.org/10.1182/blood-2003-08-2804 PubMedCrossRef

31.

Gresele P, Kleiman NS, Lopez JA, Page CP (2017) Platelets in thrombotic and non-thrombotic disorders. Pathophysiology, pharmacology and therapeutics: an update. Springer International Publishing, New YorkCrossRef

32.

Elzey BD, Sprague DL, Ratliff TL (2005) The emerging role of platelets in adaptive immunity. Cell Immunol 238:1–9. https://doi.org/10.1016/j.cellimm.2005.12.005 PubMedCrossRef

33.

Jin R, Yu S, Song Z, Zhu X, Wang C, Yan J et al (2013) Soluble CD40 ligand stimulates CD40-dependent activation of the β2 integrin Mac-1 and protein kinase C zeda (PKCζ) in neutrophils: implications for neutrophil-platelet interactions and neutrophil oxidative burst. PLoS One 8(6):e64631. https://doi.org/10.1371/journal.pone.0064631 PubMedPubMedCentralCrossRef

34.

Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL (2008) Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood 111(6):5028–5036. https://doi.org/10.1182/blood-2007-06-097410 PubMedPubMedCentralCrossRef

35.

Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ (2003) CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 92:1041–1048. https://doi.org/10.1161/01.RES.0000070111.98158.6C PubMedCrossRef

36.

Emadi S, Mirshahi M, Elalamy I, Nicolas C, Vargaftig BB, Hatmi M (1998) Cellular source of human platelet secretory phospholipase A2. Br J Haematol 100:365–373PubMedCrossRef

37.

Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S et al (2005) Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 122:379–391. https://doi.org/10.1016/j.cell.2005.06.015 PubMedPubMedCentralCrossRef

38.

Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720–3732. https://doi.org/10.1182/blood-2010-07-273417 PubMedPubMedCentralCrossRef

39.

Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA et al (2001) Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 154:485–490. https://doi.org/10.1083/jcb.200105058 PubMedPubMedCentralCrossRef

40.

Beaulieu LM, Freedman JE (2009) NFkappaB regulation of platelet function: no nucleus, no genes, no problem? J Thromb Haemost 7:1329–1332. https://doi.org/10.1111/j.1538-7836.2009.03505.x PubMedPubMedCentralCrossRef

41.

Plé H, Landry P, Benham A, Coarfa C, Gunaratne PH, Provost P (2012) The repertoire and features of human platelet microRNAs. PLoS One 7(12):e50746. https://doi.org/10.1371/journal.pone.0050746 PubMedPubMedCentralCrossRef

42.

Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK (2011) MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther 13:229. https://doi.org/10.1186/ar3377 PubMedPubMedCentralCrossRef

43.

Norling LV, Dalli J (2013) Microparticles are novel effectors of immunity. Curr Opin Pharmacol 13:570–575. https://doi.org/10.1016/j.coph.2013.05.008 PubMedCrossRef

44.

Italiano JE, Mairuhu AT, Flaumenhaft R (2010) Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol 17:578–584. https://doi.org/10.1097/MOH.0b013e32833e77ee PubMedPubMedCentralCrossRef

45.

Garcia BA, Smalley DM, Cho H, Shabanowitz J, Ley K, Hunt DF (2005) The platelet microparticle proteome. J Proteome Res 4:1516–1521. https://doi.org/10.1021/pr0500760 PubMedCrossRef

46.

Melki I, Tessandier N, Zufferey A, Boilard E (2017) Platelet microvesicles in health and disease. Platelets 28:214–221. https://doi.org/10.1080/09537104.2016.1265924 PubMedCrossRef

47.

Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C (2005) Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 25:1512–1518. https://doi.org/10.1161/01.ATV.0000170133.43608.37 PubMedCrossRef

48.

Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N et al (2012) Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res 93:633–644. https://doi.org/10.1093/cvr/cvs007 PubMedPubMedCentralCrossRef

49.

Maugeri N, Franchini S, Campana L, Baldini M, Ramirez GA, Sabbadini MG et al (2012) Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity 45:584–587. https://doi.org/10.3109/08916934.2012.719946 PubMedCrossRef

50.

Reich N, Beyer C, Gelse K, Akhmetshina A, Dees C, Zwerina J et al (2011) Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. J Cell Mol Med 15:756–762. https://doi.org/10.1111/j.1582-4934.2010.01051.x PubMedCrossRef

51.

Berckmans RJ, Nieuwland R, Böing AN, Romijn FP, Hack CE, Sturk A (2001) Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 85:639–646PubMedCrossRef

52.

Biró E, Nieuwland R, Tak PP, Pronk LM, Schaap MC, Sturk A et al (2007) Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 66:1085–1092. https://doi.org/10.1136/ard.2006.061309 PubMedPubMedCentralCrossRef

53.

Cloutier N, Tan S, Boudreau LH, Cramb C, Subbaiah R, Lahey L et al (2013) The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes. EMBO Mol Med 5:235–249. https://doi.org/10.1002/emmm.201201846 PubMedCrossRef

54.

Passacquale G, Vamadevan P, Pereira L, Hamid C, Corrigall V, Ferro A (2011) Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One 6(10):e25595. https://doi.org/10.1371/journal.pone.0025595 PubMedPubMedCentralCrossRef

55.

Barnard MR, Linden MD, Frelinger AL, Li Y, Fox ML, Furman MI et al (2005) Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost 3:2563–2570. https://doi.org/10.1111/j.1538-7836.2005.01603.x PubMedCrossRef

56.

Kim SJ, Jenne CN (2016) Role of platelets in neutrophil extracellular trap (NET) production and tissue injury. Semin Immunol 28:546–554. https://doi.org/10.1016/j.smim.2016.10.013 PubMedCrossRef

57.

Pfeiler S, Stark K, Massberg S, Engelmann B (2017) Propagation of thrombosis by neutrophils and extracellular nucleosome networks. Haematologica 102:206–213. https://doi.org/10.3324/haematol.2016.142471 PubMedPubMedCentralCrossRef

58.

Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P et al (2012) Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood 120:3007–3018. https://doi.org/10.1182/blood-2012-03-416156 PubMedCrossRef

59.

Zarbock A, Polanowska-Grabowska RK, Ley K (2007) Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev 21:99–111. https://doi.org/10.1016/j.blre.2006.06.001 PubMedCrossRef

60.

Maugeri N, Campana L, Gavina M, Covino C, De Metrio M, Panciroli C et al (2014) Activated platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J Thromb Haemost 12:2074–2088. https://doi.org/10.1111/jth.12710 PubMedCrossRef

61.

Serhan CN, Sheppard KA (1990) Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest 85:772–780. https://doi.org/10.1172/JCI114503 PubMedPubMedCentralCrossRef

62.

Gros A, Ollivier V, Ho-Tin-Noé B (2014) Platelets in inflammation: regulation of leukocyte activities and vascular repair. Front Immunol 5:678. https://doi.org/10.3389/fimmu.2014.00678 PubMedCrossRef

63.

Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ (2001) Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 115:451–459. https://doi.org/10.1046/j.1365-2141.2001.03101.x PubMedCrossRef

64.

Li N, Ji Q, Hjemdahl P (2006) Platelet-lymphocyte conjugation differs between lymphocyte subpopulations. J Thromb Haemost 4:874–881. https://doi.org/10.1111/j.1538-7836.2006.01817.x PubMedCrossRef

65.

Zamora C, Cantó E, Nieto JC, Ortiz MA, Diaz-Torné C, Diaz-Lopez C et al (2013) Functional consequences of platelet binding to T lymphocytes in inflammation. J Leukoc Biol 94:521–529. https://doi.org/10.1189/jlb.0213074 PubMedCrossRef

66.

Gerdes N, Zhu L, Ersoy M, Hermansson A, Hjemdahl P, Hu H et al (2011) Platelets regulate CD4⁺ T-cell differentiation via multiple chemokines in humans. Thromb Haemost 106:353–362. https://doi.org/10.1160/TH11-01-0020 PubMedCrossRef

67.

Zhu L, Huang Z, Stålesen R, Hansson GK, Li N (2014) Platelets provoke distinct dynamics of immune responses by differentially regulating CD4+ T-cell proliferation. J Thromb Haemost 12:1156–1165. https://doi.org/10.1111/jth.12612 PubMedCrossRef

68.

Marder W, Khalatbari S, Myles JD, Hench R, Yalavarthi S, Lustig S et al (2011) Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis 70:1550–1555. https://doi.org/10.1136/ard.2010.148031 PubMedPubMedCentralCrossRef

69.

Dinkla S, van Cranenbroek B, van der Heijden WA, He X, Wallbrecher R, Dumitriu IE et al (2016) Platelet microparticles inhibit IL-17 production by regulatory T cells through P-selectin. Blood 127:1976–1986. https://doi.org/10.1182/blood-2015-04-640300 PubMedCrossRef

70.

Cognasse F, Hamzeh-Cognasse H, Lafarge S, Chavarin P, Cogné M, Richard Y et al (2007) Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol 35:1376–1387. https://doi.org/10.1016/j.exphem.2007.05.021 PubMedCrossRef

71.

Chapman LM, Aggrey AA, Field DJ, Srivastava K, Ture S, Yui K et al (2012) Platelets present antigen in the context of MHC class I. J Immunol 189:916–923. https://doi.org/10.4049/jimmunol.1200580 PubMedPubMedCentralCrossRef

72.

Capra V, Rovati GE, Mangano P, Buccellati C, Murphy RC, Sala A (2015) Transcellular biosynthesis of eicosanoid lipid mediators. Biochim Biophys Acta 1851:377–382. https://doi.org/10.1016/j.bbalip.2014.09.002 PubMedCrossRef

73.

Folco G, Murphy RC (2006) Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 58:375–388. https://doi.org/10.1124/pr.58.3.8 PubMedCrossRef

74.

Li Z, Delaney MK, O’Brien KA, Du X (2010) Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 30:2341–2349. https://doi.org/10.1161/ATVBAHA.110.207522 PubMedPubMedCentralCrossRef

75.

Marcus AJ, Broekman MJ, Safier LB, Ullman HL, Islam N, Sherhan CN et al (1982) Formation of leukotrienes and other hydroxy acids during platelet-neutrophil interactions in vitro. Biochem Biophys Res Commun 109:130–137PubMedCrossRef

76.

Aldrovandi M, Hinz C, Lauder SN, Podmore H, Hornshaw M, Slatter DA et al (2017) DioxolaneA3-phosphatidylethanolamines are generated by human platelets and stimulate neutrophil integrin expression. Redox Biol 11:663–672. https://doi.org/10.1016/j.redox.2017.01.001 PubMedPubMedCentralCrossRef

77.

Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8:349–361. https://doi.org/10.1038/nri2294 PubMedPubMedCentralCrossRef

78.

Fierro IM, Serhan CN (2001) Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. Braz J Med Biol Res 34:555–566. https://doi.org/10.1590/S0100-879X2001000500002 PubMedCrossRef

79.

Fredman G, Van Dyke TE, Serhan CN (2010) Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol 30:2005–2013. https://doi.org/10.1161/ATVBAHA.110.209908 PubMedPubMedCentralCrossRef

80.

Abdulnour RE, Dalli J, Colby JK, Krishnamoorthy N, Timmons JY, Tan SH et al (2014) Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective. Proc Natl Acad Sci U S A 111:16526–16531. https://doi.org/10.1073/pnas.1407123111 PubMedPubMedCentralCrossRef

81.

Lannan KL, Spinelli SL, Blumberg N, Phipps RP (2017) Maresin 1 induces a novel pro-resolving phenotype in human platelets. J Thromb Haemost 15:802–813. https://doi.org/10.1111/jth.13620 PubMedPubMedCentralCrossRef

82.

Hong S, Lu Y, Tian H, Alapure BV, Wang Q, Bunnell BA et al (2014) Maresin-like lipid mediators are produced by leukocytes and platelets and rescue reparative function of diabetes-impaired macrophages. Chem Biol 21:1318–1329. https://doi.org/10.1016/j.chembiol.2014.06.010 PubMedPubMedCentralCrossRef

83.

Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M (2014) Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology 53:2143–2154. https://doi.org/10.1093/rheumatology/keu224 PubMedPubMedCentralCrossRef

84.

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76:17–28. https://doi.org/10.1136/annrheumdis-2016-209775 PubMedCrossRef

85.

Habets KL, Huizinga TW, Toes RE (2013) Platelets and autoimmunity. Eur J Clin Invest 43:746–757. https://doi.org/10.1111/eci.12101 PubMedCrossRef

86.

Kehrel E, Brodde BF M (2013) State of the art in platelet function testing. Transfus Med Hemother 40:73–86. https://doi.org/10.1159/000350469 CrossRef

87.

Lood C, Tydén H, Gullstrand B, Sturfelt G, Jönsen A, Truedsson L et al (2014) Platelet activation and anti-phospholipid antibodies collaborate in the activation of the complement system on platelets in systemic lupus erythematosus. PLoS One 9(6):e99386. https://doi.org/10.1371/journal.pone.0099386 PubMedPubMedCentralCrossRef

88.

Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD (2011) Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 31:153–164. https://doi.org/10.1007/s00296-010-1446-x PubMedCrossRef

89.

Harifi G, Sibilia J (2016) Pathogenic role of platelets in rheumatoid arthritis and systemic autoimmune diseases. Perspectives and therapeutic aspects. Saudi Med J 37:354–360. https://doi.org/10.15537/smj.2016.4.14768 PubMedPubMedCentralCrossRef

90.

Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA et al (2008) Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 75:291–294. https://doi.org/10.1016/j.jbspin.2007.06.016 PubMedCrossRef

91.

Boilard E, Blanco P, Nigrovic PA (2012) Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 8:534–542. https://doi.org/10.1038/nrrheum.2012.118 PubMedCrossRef

92.

Işık M, Şahin H, Hüseyin E (2014) New platelet indices as inflammatory parameters for patients with rheumatoid arthritis. Eur J Rheumatol 1:144–146. https://doi.org/10.5152/eurjrheumatol.2014.140023 PubMedPubMedCentralCrossRef

93.

Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA (2002) Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 46:1498–1503. https://doi.org/10.1002/art.10312 PubMedCrossRef

94.

Mott PJ, Lazarus AH (2013) CD44 antibodies and immune thrombocytopenia in the amelioration of murine inflammatory arthritis. PLoS One 8(6):e65805. https://doi.org/10.1371/journal.pone.0065805 PubMedPubMedCentralCrossRef

95.

Habets KL, Trouw LA, Levarht EW, Korporaal SJ, Habets PA, de Groot P et al (2015) Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. Arthritis Res Ther 17:209. https://doi.org/10.1186/s13075-015-0665-7 PubMedPubMedCentralCrossRef

96.

Sokolove J, Brennan MJ, Sharpe O, Lahey LJ, Kao AH, Krishnan E et al (2013) Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 65:1719–1724. https://doi.org/10.1002/art.37961 PubMedPubMedCentralCrossRef

97.

Weyrich AS, Zimmerman GA (2004) Platelets: signaling cells in the immune continuum. Trends Immunol 25:489–495. https://doi.org/10.1016/j.it.2004.07.003 PubMedCrossRef

98.

Vázquez-Del Mercado M, Nuñez-Atahualpa L, Figueroa-Sánchez M, Gómez-Bañuelos E, Rocha-Muñoz AD, Martín-Márquez BT et al (2015) Serum levels of anticyclic citrullinated peptide antibodies, interleukin-6, tumor necrosis factor-α, and C-reactive protein are associated with increased carotid intima-media thickness: a cross-sectional analysis of a cohort of rheumatoid arthritis patients without cardiovascular risk factors. Biomed Res Int. 2015:342649. https://doi.org/10.1155/2015/342649 PubMedPubMedCentralCrossRef

99.

Verschoor A, Langer HF (2013) Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost 110:910–919. https://doi.org/10.1160/TH13-02-0102 PubMedCrossRef

100.

Gerli R, Bartoloni Bocci E, Sherer Y, Vaudo G, Moscatelli S, Shoenfeld Y (2008) Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 67:724–725. https://doi.org/10.1136/ard.2007.073718 PubMedCrossRef

101.

Barbarroja N, Pérez-Sanchez C, Ruiz-Limon P, Castro-Villegas C, Aguirre MA, Carretero R et al (2014) Anticyclic citrullinated protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol 34:2706–2716. https://doi.org/10.1161/ATVBAHA.114.304475 PubMedCrossRef

102.

Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME et al (2010) Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327:580–583. https://doi.org/10.1126/science.1181928 PubMedPubMedCentralCrossRef

103.

Kojima F, Naraba H, Sasaki Y, Beppu M, Aoki H, Kawai S (2003) Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum 48:2819–2828. https://doi.org/10.1002/art.11261 PubMedCrossRef

104.

Bartok B, Firestein GS (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233:233–255. https://doi.org/10.1111/j.0105-2896.2009.00859.x PubMedPubMedCentralCrossRef

105.

Jüngel A, Distler O, Schulze-Horsel U, Huber LC, Ha HR, Simmen B et al (2007) Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1. Arthritis Rheum 56:3564–3574. https://doi.org/10.1002/art.22980 PubMedCrossRef

106.

Boilard E, Larabee K, Shnayder R, Jacobs K, Farndale RW, Ware J et al (2011) Platelets participate in synovitis via Cox-1-dependent synthesis of prostacyclin independently of microparticle generation. J Immunol 186:4361–4366. https://doi.org/10.4049/jimmunol.1002857 PubMedPubMedCentralCrossRef

107.

Giera M, Ioan-Facsinay A, Toes R, Gao F, Dalli J, Deelder AM et al (2012) Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim Biophys Acta 1821:1415–1424. https://doi.org/10.1016/j.bbalip.2012.07.011 PubMedPubMedCentralCrossRef

108.

Chan MM, Moore AR (2010) Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J Immunol 184:6418–6426. https://doi.org/10.4049/jimmunol.0903816 PubMedPubMedCentralCrossRef

109.

Burbano C, Rojas M, Vásquez G, Castaño D. (2015) Microparticles that form immune complexes as modulatory structures in autoimmune responses. Mediators Inflamm. 2015:267590. https://doi.org/10.1155/2015/267590 PubMedPubMedCentralCrossRef

110.

Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, Klareskog L et al (2005) Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 7:R458-467. https://doi.org/10.1186/ar1697 CrossRef

111.

Burska AN, Hunt L, Boissinot M, Strollo R, Ryan BJ, Vital E et al (2014) Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm 2014:492873. https://doi.org/10.1155/2014/492873 PubMedPubMedCentralCrossRef

112.

Maugeri N, Rovere-Querini P, Manfredi AA (2016) Disruption of a regulatory network consisting of neutrophils and platelets fosters persisting inflammation in rheumatic diseases. Front Immunol 7:182. https://doi.org/10.3389/fimmu.2016.00182 PubMedPubMedCentralCrossRef

113.

Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS et al (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 5:178ra40. https://doi.org/10.1126/scitranslmed.3005580 PubMedPubMedCentralCrossRef

114.

Mauler M, Bode C, Duerschmied D (2016) Platelet serotonin modulates immune functions. Hamostaseologie 36:11–16. https://doi.org/10.5482/HAMO-14-11-0073 PubMedCrossRef

115.

Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE (2015) Pathogenesis of systemic sclerosis. Front Immunol 6:272. https://doi.org/10.3389/fimmu.2015.00272 PubMedPubMedCentralCrossRef

116.

McCarthy EM, Moreno-Martinez D, Wilkinson FL, McHugh NJ, Bruce IN, Pauling JD et al (2017) Microparticle subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of connective tissue disease. BBA Clin 7:16–22. https://doi.org/10.1016/j.bbacli.2016.11.003 PubMedCrossRef

117.

Ramirez GA, Franchini S, Rovere-Querini P, Sabbadini MG, Manfredi AA, Maugeri N (2012) The role of platelets in the pathogenesis of systemic sclerosis. Front Immunol 3:160. https://doi.org/10.3389/fimmu.2012.00160 PubMedPubMedCentralCrossRef

118.

Silveri F, De Angelis R, Poggi A, Muti S, Bonapace G, Argentati F et al (2001) Relative roles of endothelial cell damage and platelet activation in primary Raynaud’s phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 30:290–296PubMedCrossRef

119.

Pamuk GE, Turgut B, Pamuk ON, Vural O, Demir M, Cakir N (2007) Increased circulating platelet-leucocyte complexes in patients with primary Raynaud’s phenomenon and Raynaud’s phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagul Fibrinolysis 18:297–302. https://doi.org/10.1097/MBC.0b013e328010bd05 PubMedCrossRef

120.

Postlethwaite AE, Chiang TM (2007) Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 19:574–579. https://doi.org/10.1097/BOR.0b013e3282eeb3a4 PubMedCrossRef

121.

Beretta L, Cossu M, Marchini M, Cappiello F, Artoni A, Motta G et al (2008) A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation. Arthritis Res Ther 10(5):R103. https://doi.org/10.1186/ar2495 PubMedPubMedCentralCrossRef

122.

Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M (2010) Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 14:1241–1254. https://doi.org/10.1111/j.1582-4934.2010.01027.x PubMedPubMedCentralCrossRef

123.

Hirigoyen D, Burgos PI, Mezzano V, Duran J, Barrientos M, Saez CG et al (2015) Inhibition of angiogenesis by platelets in systemic sclerosis patients. Arthritis Res Ther 17:332. https://doi.org/10.1186/s13075-015-0848-2 PubMedPubMedCentralCrossRef

124.

van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L et al (2014) Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 370:433–443. https://doi.org/10.1056/NEJMoa1114576 PubMedCrossRef

125.

Maidhof W, Hilas O (2012) Lupus: an overview of the disease and management options. P T 37:240–249PubMedPubMedCentral

126.

Jung JH, Soh MS, Ahn YH, Um YJ, Jung JY, Suh CH et al (2016) Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. Medicine (Baltimore) 95(6):e2818. https://doi.org/10.1097/MD.0000000000002818 CrossRef

127.

Dieker J, Tel J, Pieterse E, Thielen A, Rother N, Bakker M et al (2016) Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis Rheumatol 68:462–472. https://doi.org/10.1002/art.39417 PubMedCrossRef

128.

Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS (2017) Elevated levels of soluble CD40 ligand are associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol 35:823–830PubMed

129.

Becker-Merok A, Østli-Eilersten G, Lester S, Nossent J (2013) Circulating interferon-α2 levels are increased in the majority of patients with systemic lupus erythematosus and are associated with disease activity and multiple cytokine activation. Lupus 22:155–163. https://doi.org/10.1177/0961203312468964 PubMedCrossRef

130.

Lood C, Amisten S, Gullstrand B, Jönsen A, Allhorn M, Truedsson L et al (2010) Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood 116:1951–1957. https://doi.org/10.1182/blood-2010-03-274605 PubMedCrossRef

131.

Ullal AJ, Reich CF, Clowse M, Criscione-Schreiber LG, Tochacek M, Monestier M et al (2011) Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. J Autoimmun 36:173–180. https://doi.org/10.1016/j.jaut.2011.02.001 PubMedCrossRef

132.

Nielsen CT, Østergaard O, Stener L, Iversen LV, Truedsson L, Gullstrand B et al (2012) Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum 64:227–236. https://doi.org/10.1002/art.34381 CrossRef

133.

Ryan BJ, Nissim A, Winyard PG (2014) Oxidative post-translational modifications and their involvement in the pathogenesis of autoimmune diseases. Redox Biol 2:715–724. https://doi.org/10.1016/j.redox.2014.05.004 PubMedPubMedCentralCrossRef

134.

Das UN (2010) Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation. J Inflamm Res 3:143–170. https://doi.org/10.2147/JIR.S9425 PubMedPubMedCentralCrossRef

135.

Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 376:1498–1509. https://doi.org/10.1016/S0140-6736(10)60709-X PubMedCrossRef

136.

Sanna G, Bertolaccini ML, Mameli A, Hughes GR, Khamashta MA, Mathieu A (2005) Antiphospholipid antibodies in patients with scleroderma: prevalence and clinical significance. Ann Rheum Dis 64:1795–1796. https://doi.org/10.1136/ard.2005.038430 PubMedPubMedCentralCrossRef

137.

Kim KJ, Baek IW, Park KS, Kim WU, Cho CS (2017) Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis. Lupus 26:88–94. https://doi.org/10.1177/0961203316658557 PubMedCrossRef

138.

Baroni G, Banzato A, Bison E, Denas G, Zoppellaro G, Pengo V (2017) The role of platelets in antiphospholipid syndrome. Platelets. 2017:1–5. https://doi.org/10.1080/09537104.2017.1280150 CrossRef

139.

Jy W, Tiede M, Bidot CJ, Horstman LL, Jimenez JJ, Chirinos J et al (2007) Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res 121:319–325. https://doi.org/10.1016/j.thromres.2007.04.014 PubMedCrossRef

140.

Yazici S, Yazici M, Erer B, Calik Y, Ozhan H, Ataoglu S (2010) The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets 21:122–125. https://doi.org/10.3109/09537100903474373 PubMedCrossRef

141.

Safak S, Uslu AU, Serdal K, Turker T, Soner S, Lutfi A (2014) Association between mean platelet volume levels and inflammation in SLE patients presented with arthritis. Afr Health Sci 14:919–924. https://doi.org/10.4314/ahs.v14i4.21 PubMedPubMedCentralCrossRef

142.

Delgado-García G, Galarza-Delgado D, Colunga-Pedraza I, Borjas-Almaguer OD, Mandujano-Cruz I, Benavides-Salgado D et al (2016) Mean platelet volume is decreased in adults with active lupus disease. Rev Bras Reumatol 56:504–508. https://doi.org/10.1016/j.rbr.2015.12.003 CrossRef

143.

Huang ZY, Chien P, Indik ZK, Schreiber AD (2011) Human platelet FcγRIIA and phagocytes in immune-complex clearance. Mol Immunol 48:691–696. https://doi.org/10.1016/j.molimm.2010.11.017 PubMedCrossRef

144.

Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, Kitas GD (2010) Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy. Rheumatol Int 30:1125–1129. https://doi.org/10.1007/s00296-009-1345-1 PubMedCrossRef

145.

Noris P, Melazzini F, Balduini CL (2016) New roles for mean platelet volume measurement in the clinical practice? Platelets 27:607–612. https://doi.org/10.1080/09537104.2016.1224828 PubMedCrossRef

146.

Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulou F, Labrianou I (2010) Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia 14:28–32PubMedPubMedCentral

147.

Harrison P, Goodall AH (2016) Studies on mean platelet volume (MPV)—new editorial policy. Platelets 27:605–606. https://doi.org/10.1080/09537104.2016.1225467 PubMedCrossRef

148.

De Luca G, Verdoia M, Cassetti E, Schaffer A, Di Giovine G, Bertoni A et al (2013) Mean platelet volume is not associated with platelet reactivity and the extent of coronary artery disease in diabetic patients. Blood Coagul Fibrinolysis 24:619–624. https://doi.org/10.1097/MBC.0b013e328360c75a PubMedCrossRef

149.

Huczek Z, Kochman J, Filipiak KJ, Horszczaruk GJ, Grabowski M, Piatkowski R et al (2005) Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 46:284–290. https://doi.org/10.1016/j.jacc.2005.03.065 PubMedCrossRef

150.

Makowski M, Smorag I, Makowska J, Bissinger A, Grycewicz T, Paśnik J et al (2017) Platelet reactivity and mean platelet volume as risk markers of thrombogenesis in atrial fibrillation. Int J Cardiol 235:1–5. https://doi.org/10.1016/j.ijcard.2017.03.023 PubMedCrossRef

151.

Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B et al (2010) Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 8:148–156. https://doi.org/10.1111/j.1538-7836.2009.03584.x PubMedCrossRef

152.

Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6(10):a016295. https://doi.org/10.1101/cshperspect.a016295 PubMedPubMedCentralCrossRef

153.

Kaplan MJ (2010) Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. Rheum Dis Clin North Am 36:405–426. https://doi.org/10.1016/j.rdc.2010.02.002 PubMedPubMedCentralCrossRef

154.

Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P et al (2010) Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-κB inhibition via HGF. J Cell Physiol 225:757–766. https://doi.org/10.1002/jcp.22274 PubMedCrossRef

155.

Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT (2004) Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 91:4–15. https://doi.org/10.1160/TH03-07-0440 PubMedCrossRef

156.

Lippross S, Moeller B, Haas H, Tohidnezhad M, Steubesand N, Wruck CJ et al (2011) Intraarticular injection of platelet-rich plasma reduces inflammation in a pig model of rheumatoid arthritis of the knee joint. Arthritis Rheum 63:3344–3353. https://doi.org/10.1002/art.30547 PubMedCrossRef

157.

Serhan CN, Savill J (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6:1191–1197. https://doi.org/10.1038/ni1276 PubMedCrossRef

158.

Kapur R, Zufferey A, Boilard E, Semple JW (2015) Nouvelle cuisine: platelets served with inflammation. J Immunol 194:5579–5587. https://doi.org/10.4049/jimmunol.1500259 PubMedCrossRef

Title: From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders
Authors: Zuzanna Małgorzata Łukasik
Marcin Makowski
Joanna Samanta Makowska
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Rheumatology International / Issue 6/2018
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-018-4001-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain

Pseudogout among Patients Fulfilling a Billing Code Algorithm for Calcium Pyrophosphate Deposition Disease

Sexual health in patients with rheumatoid arthritis and the association between physical fitness and sexual function: a cross-sectional study

Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives

Association between memory B-cells and clinical and immunological features of primary Sjögren’s syndrome and Sicca patients

Glenohumeral osteoarthritis: frequency of underlying diagnoses and the role of arm dominance—a retrospective analysis in a community-based musculoskeletal practice

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page